Clinical trial · Observational

An Italian Experience on Grade 3b Follicular Lymphoma

NCT02927717CI-TRIAL-00024189FL3b-Oss-2015unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Grade 3b Follicular Lymphoma	Grade 3b Follicular Lymphoma	ONTOLOGY_EXACT	0.98

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Overall Response Rate
timeFrame
End of front-line treatment (evaluated from diagnosis up to 30 months)
description
Number of patients who achieve Complete Response or Partial Response after treatment

Secondary outcomes (2)

measure
Progression Free Survival
timeFrame
From first response to last follow-up for at least 2 years (up to 15 years)
description
Time from last response to nearest relapse or follow-up
measure
Overall Survival
timeFrame
Date of last follow-up for at least 2 years (up to 15 years)
description
Time to last follow-up or death

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Diagnosis of grade 3b Follicular Lymphoma
* Age \> 18 years
* Front-line treatment with Rituximab containing chemotherapy
* Availability of histological sample for central review

Exclusion Criteria:

* Other lymphoma diagnosis

References

Publications (0)

Data not yet available

No reference posted for this study.